Chercheur

    Caroline Laverdière , M.D.

    caroline.laverdiere@umontreal.ca
    Caroline Laverdière
    Axe de recherche
    Maladies virales, immunitaires et cancers
    Thème de recherche
    Cancers : mécanismes génétiques et moléculaires et nouvelles thérapies
    Adresse
    CHUSJ

    Téléphone
    514 345-4931 #3483

    Fax
    514 345-4884

    Titres

    • Professeur adjointe, Département de pédiatrie, Université de Montréal.
    • Directrice médicale, Clinique de suivi à long terme, CHU Sainte-Justine.
    • Responsable, Programme de leucémie aiguë lymphoblastique, CHU Sainte-Justine.
    • Investigatrice principale, Protocole Boston pour le traitement des leucémies aiguës lymphoblastiques, CHU Sainte-Justine.

    Formation

    • Formation complémentaire sur les effets à long terme chez les survivants de cancer pédiatrique, Memorial Sloan-Kettering Cancer Center, New York, 2001-2004.
    • Résidence en hémato-oncologie pédiatrique, Université de Montréal, 1999-2001.
    • Résidence en pédiatrie, Université de Montréal, 1996-1999.
    • MD, Université de Montréal, 1991-1996.

    Intérêts de recherche

    • Effets à long terme chez les survivants de cancer pédiatrique;
    • Pharmacogénomique dans la leucémie aiguë lymphoblastique.

    Présentations

    • Les survivants de cancers pédiatriques. Conférence sur invitation. Service d’hématologie-oncologie pédiatrique, Institut Gustave Roussy, Paris, France, mars 2009.
    • Suivi des jeunes adultes survivants de cancer : expérience québécoise. Conférence sur invitation. Colloque sur le vécu des adolescents atteints de cancer, CHU de Rouen, Rouen, France, mars 2009.
    • Les cancers pédiatriques : les grandes avancées et les survivants. Conférence publique sur invitation. Belles Soirées de l’Université de Montréal, novembre 2008.

    Dans le cadre des Rendez-vous d'hémato-oncologie pédiatrique

    Le suivi à long terme des survivants de cancers pédiatriques: l'expérience québécoise et les défis de la recherche

Publications

Pharmacogenetic considerations for acute lymphoblastic leukemia therapies - Dulucq S, Laverdière C, Sinnett D, Krajinovic M. Pharmacogenetic considerations for acute lymphoblastic leukemia therapies. Expert Opin Drug Metab Toxicol 2014; 10(5): 699-719.

Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia - Leblicq C, Laverdière C, Décarie JC, Delisle JF, Isler M, Moghrabi A, Chabot G, Alos N. Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer 2013; 60(5): 741-747.

The development of bone mineral lateralization in the arms - Siminoski K, Lee KC, Abish S, Alos N, Bell L, Blydt-Hansen TD, Couch R, Cummings E, Ellsworth J, Feber J, Fernandez C, Halton J, Huber AM, Israels S, Jurencak R, Lang B, Laverdière C, LeBlanc C, Lewis V, Midgley J, Miettunen P, Oen K, Phan V, Pinsk M, Rauch F, Rodd C, Roth J, Saint-Cyr C, Scuccimarri R, Stephure D, Taback S, Wilson B, Ward LM, the Canadian STOPP Consortium (National Pediatric Bone Health Working Group). The development of bone mineral lateralization in the arms. Osteoporosis Int 2013; 24(3): 999-1006.

Imaging of early modification in cardiomyopthy: the doxorubicin-induced model - Aissiou M, Périé-Curnier D, Cheriet F, Dahdah NS, Laverdière C, Curnier D. Imaging of early modification in cardiomyopthy: the doxorubicin-induced model. Int J Cardiovasc Imag 2013; 29(7): 1459-1476.

Assessment of gross motor skills and phenotype profile in children 9-11 years of age in survivors of acute lymphoblastic leukemia - Léoné M, Viret P, Bui H, Laverdière C, Kalinova E, Comtois AS. Assessment of gross motor skills and phenotype profile in children 9-11 years of age in survivors of acute lymphoblastic leukemia. Pediatr Blood Cancer 2013; (sous presse).

Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway in childhood acute lymphoblastic leukemia outcome - Sanchez R, St-Cyr J, Lalonde ME, Healy J, Richer C, Gagné V, Laverdière C, Silverman LB, Sallan SE, Neuberg D, Kutok JL, Kritikou EA, Krajinovic M, Sinnett D. Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway in childhood acute lymphoblastic leukemia outcome. Haematologica 2013; (sous presse).

Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia - Gagné V, Rousseau J, Labuda M, Sharif-Askari B, Brukner I, Laverdière C, Ceppi F, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Sinnett D, Krajinovic M. Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia. Clin Cancer Res 2013; 19(18): 5240-5249.

Expression of the senescence marker p16INK4a in skin biopsies of acute lymphoblastic leukemia survivors: a pilot study - Marcoux S, Le ON, Langlois-Pelletier C, Laverdière C, Hatami A, Robaey P, Beauséjour C. Expression of the senescence marker p16INK4a in skin biopsies of acute lymphoblastic leukemia survivors: a pilot study. Radiat Oncol 2013; 8(1): 252.

Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia - Lipshultz SE, Lipsitz SR, Kutok JL, Miller TL, Colan SD, Neuberg DS, Stevenson K, Fleming MD, Sallan SE, Franco VI, Henkel JM, Asselin BL, Athale UH, Clavell LA, Michon B, Laverdière C, Larsen E, Kelly K, Silverman LB. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer 2013; 119(19): 3555-3562.

Role of NOS3 DNA variants in externalizing behavioral problems observed in childhood leukemia survivors - Marcoux S, Robaey P, Gahier A, Labuda M, Rousseau J, Sinnett D, Moghrabi A, Laverdière C, Krajinovic M. Role of NOS3 DNA variants in externalizing behavioral problems observed in childhood leukemia survivors. J Pediatr Hematol Oncol 2013; 35(4): e157-162.

Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01 - Vrooman LM, Stevenson K, Supko J, O'Brien J, Dahlberg SE, Asselin BL, Athale UH, Clavell LA, Kelly K, Kutok JL, Laverdière C, Lipshultz SE, Michon B, Schorin M, Relling MV, Cohen HJ, Neuberg DS, Sallan SE, Silverman LB. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 2013; 31(9): 1202-1210.

Predictive factors of internalized and externalized behavioral problems in children treated for acute lymphoblastic leukemia - Marcoux S, Robaey P, Krajinovic M, Moghrabi A, Laverdière C. Predictive factors of internalized and externalized behavioral problems in children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer 2012; 58(6): 971-977.

Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia - Ansari M, Sauty G, Labuda M, Gagné V, Rousseau J, Moghrabi A, Laverdière C, Sinnett D, Krajinovic M. Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia. Pharmacogenomics 2012; 12(5): 386-394.

Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome - Feber J, Gaboury I, Ni A, Alos N, Arora S, Bell L, Blydt-Hansen TD, Clarson C, Filler G, Hay J, Hébert D, Lentle B, Matzinger M, Midgley J, Moher D, Pinsk M, Rauch F, Rodd C, Shenouda N, Siminoski K, Ward LM, Laverdière C, Canadian STOPP Consortium. Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome. Osteoporosis Int 2012; 23(2): 751-760.

Continuous versus bolus infusion of Doxorubicin in children with ALL: long-term cardiac outcomes - Lipshultz SE, Miller TL, Lipsitz SR, Neuberg DS, Dahlberg SE, Colan SD, Silverman LB, Henkel JM, Franco VI, Cushman LL, Asselin BL, Clavell LA, Athale UH, Michon B, Laverdière C, Schorin M, Larsen E, Usmani N, Sallan SE, Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium. Continuous versus bolus infusion of Doxorubicin in children with ALL: long-term cardiac outcomes. Pediatrics 2012; 130(6): 1003-1111.

High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy - Alos N, Grant R, Ramsay T, Halton J, Cummings E, Miettunen P, Abish S, Atkinson S, Barr R, Cabral DA, Cairney E, Couch R, Dix D, Fernandes CV, Hay J, Israels S, Laverdière C, Lentle B, Lewis V, Matzinger M, Rodd C, Shenouda N, Stein R, Stephure D, Taback S, Wilson B, Williams K, Rauch F, Siminoski K, Ward LM. High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy. J Clin Oncol 2012; 30(22): 2760-2767.

Anatomical distribution of vertebral fractures: comparison of pediatric and adult spines - Siminoski K, Lee KC, Jen H, Warshawski R, Matzinger M, Shenouda N, Charron M, Coblentz C, Dubois J, Kloiber R, Nadel H, O'Brien K, Reed M, Sparrow K, Webber C, Lentle B, Ward LM, Laverdière C, Alos N, STOPP Consortium. Anatomical distribution of vertebral fractures: comparison of pediatric and adult spines. Osteoporosis Int 2012; 23(7): 1999-2008.

Changes in cardiac biomarkers during Doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes - Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale UH, Clavell LA, Laverdière C, Michon B, Schorin M, Sallan SE. Changes in cardiac biomarkers during Doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012; 30(10): 1042-1049.

Health-related quality of life among children with acute lymphoblastic leukemia - Furlong W, Rae C, Feeny D, Gelber RD, Laverdière C, Michon B, Silverman LB, Sallan SE, Barr R. Health-related quality of life among children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2012; 59(4): 717-724.

Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study - Rodd C, Lang B, Ramsay T, Alos N, Huber AM, Cabral DA, Scuccimarri R, Miettunen P, Roth J, Atkinson S, Couch R, Cummings E, Dent P, Ellsworth J, Hay J, Houghton K, Jurencak R, Larché M, LeBlanc C, Oen K, Saint-Cyr C, Stein R, Stephure DK, Taback S, Lentle B, Matzinger M, Shenouda N, Moher D, Rauch F, Siminoski K, Ward LM, Laverdière C, Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium. Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study. Arthritis Care Res (Hoboken) 2012; 64(1): 122-131.

The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium - Vrooman LM, Neuberg DS, Stevenson K, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly K, Larson EC, Laverdière C, Michon B, Schorin M, Schwartz CL, Cohen HJ, Lipshultz SE, Silverman LB, Sallan SE. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer 2011; 47(9): 1373-1379.

ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia - Rousseau J, Gagné V, Labuda M, Beaubois C, Sinnett D, Laverdière C, Moghrabi A, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Krajinovic M. ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood 2011; 118(22): 5883-5890.

Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders - Huber AM, Gaboury I, Cabral DA, Lang B, Ni A, Stephure DK, Taback S, Dent P, Ellsworth J, LeBlanc C, Saint-Cyr C, Scuccimarri R, Hay J, Lentle B, Matzinger M, Shenouda N, Moher D, Rauch F, Siminoski K, Ward LM, Alos N, Laverdière C, Phan V, Dubois J, Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium. Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. Arthritis Care Res (Hoboken) 2010; 62(4): 516-526.

Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000) - Silverman LB, Stevenson K, O'Brien J, Asselin BL, Barr R, Clavell LA, Cole PD, Kelly K, Laverdière C, Michon B, Schorin M, Schwartz CL, O'Holleran EW, Neuberg DS, Cohen HJ, Sallan SE. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2010; 24(2): 320-334.

Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia - Silverman LB, Supko J, Stevenson K, Woodard CE, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly K, Laverdière C, Michon B, Schorin M, Schwartz CL, O'Brien K, Cohen HJ, Sallan SE. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood 2010; 115(7): 1351-1353.

Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia - Vrooman LM, Supko J, Neuberg DS, Asselin BL, Athale UH, Clavell LA, Kelly K, Laverdière C, Michon B, Schorin M, Cohen HJ, Sallan SE, Silverman LB. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010; 54(2): 199-205.

Ionizing radiation-induced long-term expression of senescence markers in mice is independent of p53 and immune status - Lê O, Rodier F, Fontaine F, Coppe JP, Campisi J, Degregori J, Laverdière C, Kokta V, Haddad E, Beauséjour C. Ionizing radiation-induced long-term expression of senescence markers in mice is independent of p53 and immune status. Aging Cell 2010; 9(3): 398-409.

Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study - Laverdière C, Liu Q, Yasiu Y, Nathan PC, Gurney JG, Stovall M, Diller L, Cheung NK, Wolden S, Robison LL, Sklar CA. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101(16): 1131-1140.

Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia - Vrooman LM, Supko J, Neuberg D, Asselin BL, Athale UH, Clavell LA, Kelly K, Laverdière C, Michon B, Schorin M, Kutok JL, Cohen HJ, Sallan SE, Silverman LB. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2009; (sous presse).

DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia - Al-Shakfa F, Dulucq S, Brukner I, Milacic I, Ansari M, Beaulieu P, Moghrabi A, Laverdière C, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Sinnett D, Krajinovic M. DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia. Clin Cancer Res 2009; 15(22): 6931-6938.

Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia - Ansari M, Sauty G, Labuda D, Gagné V, Laverdière C, Moghrabi A, Sinnett D, Krajinovic M. Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood 2009; 114(7): 1383-1386.

Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program - Halton J, Gaboury I, Grant R, Alos N, Cummings E, Matzinger M, Shenouda N, Lentle B, Abish S, Atkinson S, Cairney E, Dix D, Israels S, Stephure DK, Wilson B, Hay J, Moher D, Rauch F, Siminoski K, Ward L, Laverdière C, Phan V, Dubois J, Canadian STOPP Consortium. Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program. J Bone Miner Res 2009; 24(7): 1326-1334.

Endocrine late effects of childhood cancer therapy: a report from the Children's Oncology Group - Nandagopal R, Laverdière C, Mulrooney D, Hudson M, Meacham L. Endocrine late effects of childhood cancer therapy: a report from the Children's Oncology Group. Horm Res 2008; 69(2): 65-74.

Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma - Laverdière C, Hoang BH, Yang R, Sowers R, Qin J, Meyers P, Huvos A, Healey JH, Gorlick R. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005; 11(7): 2561-2567.

À propos de cette page

Créée le 22 juillet 2014
Signaler ou faire une remarque

Chaque dollar compte !

Merci de votre générosité.

Ce sont les donateurs comme vous qui nous permettent d’accélérer la recherche, de guérir, à chaque année, plus d’enfants et continuer d’offrir un des meilleurs niveaux de santé au monde.

Il est également possible de donner par la poste ou de donner par téléphone au numéro sans frais

1-888-235-DONS (3667)

Nous contacter

514 345-4931

Légal

© 2006-2014 Centre de recherche du CHU Sainte-Justine.
Tous droits réservés.
Avis légaux  Confidentialité  Sécurité

Avertissement

Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine